Bobbi Pritt, MD, MS, FCAP, CAP Council on Scientific Affairs Chair, discusses a phased approach set forth in the LDT final rule. "That means the laboratory has to have a mechanism for receiving those complaints," said Dr. Pritt.
For the full article click here: FDA fall IVD roundtable avoids LDT questions